ASCO and WHO to collaborate on quality indicators for cancer facilities

Comment: Addition of ixazomib to pomalidomide and dexamethasone improves survival for multiple myeloma patients

Time-limited venetoclax-obinutuzumab +/- ibrutnib surpasses chemoimmunotherapy in frontline chronic lymphocytic leukaemia

Quizartinib advances overall survival in acute myeloid leukaemia patients

Spotlight on global cancer control at ASCO 2022

UICC announces global coalition to increase access to essential cancer medicines in low and lower middle-income countries

ASCO 2022: Highlights and analysis

Comment: Phase III assessment of topotecan, cyclophosphamide and high-dose ifosfamide for refractory Ewing sarcoma patients

Phase III assessment of topotecan, cyclophosphamide and high-dose ifosfamide for refractory Ewing sarcoma patients

High-dose ifosfamide standard of care for recurrent and primary refractory ewing sarcoma

Afamitresgene autoleucel (Formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma

AL3818 hydrochloride monotherapy in subjects with metastatic or advanced synovial sarcoma